VESTAR FILES PATENT INFRINGEMENT LAWSUIT IN UNITED KINGDOM AGAINST LIPOSOME TECHNOLOGY, INC.
SAN DIMAS, Calif., March 1 /PRNewswire/ -- Vestar, Inc. (NASDAQ: VSTR) today announced that it has filed a patent infringement lawsuit against Liposome Technology, Inc. of Menlo Park, Calif. The lawsuit, filed in the Patents County Court in the United Kingdom, alleges that Doxil, Liposome Technology's investigational anticancer product, infringes Vestar's European Patent (U.K.) No. 0179444 on tumor targeting. Vestar's patent covers the targeting to tumors of liposomes containing chemotherapeutic agents. Doxil contains the anticancer agent doxorubicin, and is currently undergoing clinical trials. Vestar, headquartered in San Dimas, Calif., develops, manufactures and markets pharmaceuticals to treat patients with cancer and serious infections, including AIDS. Since 1989, Vestar has been marketing in Europe AmBisome(R), a liposomal formulation of amphotericin B, to treat systemic fungal infections. DaunoXome(R), a liposomal formulation of the chemotherapeutic agent daunorubicin, is Vestar's second major product, for which a New Drug Application was filed with the FDA in February 1993. Among the company's proprietary drug delivery technologies are liposomes to encapsulate pharmaceuticals, and lipid prodrug technology for the development of orally active compounds. -0- 3/1/93 /CONTACT: Michael E. Hart, chief financial officer, Vestar, Inc. 909-394-4119; Marcia A. Kean, executive vice president, Feinstein Partners, Inc., 617-577-8110/ (VSTR)
CO: Vestar, Inc. ST: California IN: MTC SU:
DJ -- NE009 -- 1394 03/01/93 11:54 EST
|Printer friendly Cite/link Email Feedback|
|Date:||Mar 1, 1993|
|Previous Article:||SWIFT TRANSPORTATION CO. INC. ANNOUNCES SLOWDOWN IN FIRST QUARTER REVENUES|
|Next Article:||BITSTREAM ROLLS OUT NEW NOVELTY FONT PACKS FOR WINDOWS 3.1, LAUNCHES FIRST LI'L BITS FONT PACKS FOR THE MACINTOSH|